ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 096

Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study

Isaac Miller1, Kenneth Nobleza1, Duc Nguyen1, Beth Van Horne2, Christopher Greeley2, Marietta DeGuzman3, Amit Thakral3, Olivia Kwan4 and Sarah Molina5, 1Baylor College of Medicine, 2Baylor College of Medicine, Department of Pediatrics; Texas Children's Hospital, Division of Public Health Pediatrics, 3Baylor College of Medicine, Houston, TX, 4Baylor College of Medicine; Texas Children's Hospital, 5Baylor College of Medicine, Texas Children's Hospital

Meeting: 2026 Pediatric Rheumatology Symposium

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Date: Friday, March 20, 2026

Title: Posters: Clinical and Therapeutic Aspects II

Session Time: 5:00PM-6:00PM

Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) is a chronic, multisystem autoimmune disease characterized by high early disease activity and healthcare utilization. In adults, increased emergency room (ER) and hospitalization rates have been linked to disease activity, poor follow-up, and sociodemographic factors such as public health insurance and non-White race. Pediatric data remains limited. This study aimed to identify clinical and sociodemographic factors, including neighborhood opportunity (Childhood Opportunity Index, COI), associated with ER utilization among children with new-onset SLE.

Methods: A retrospective chart review of cSLE diagnosed before age 18 between January 2022 and June 2024 was done at a single, large tertiary center in southeastern United States. Data from the first year after diagnosis (included demographics, clinical features, treatment, and healthcare utilization) were summarized and compared across subgroups of COI and ER utilization. Negative binomial regression model was used to identify factors associated with ER visit frequency.

Results: Sixty patients were included: 83.3% females, 57% Hispanic; median age 15 years (IQR 13 -16). Median time from symptom onset to diagnosis was 3 months (IQR 1-6). Half had Medicaid or CHIP coverage; eight were uninsured. Major organ involvement at onset was hematologic (68%), cutaneous (58%), arthritis (55%), and renal (40%). Median SLEDAI at diagnosis was 11 (IQR 7 -17). COI mapping showed 65% lived in low/very low, 13% in moderate, and 22% in high/very high opportunity neighborhoods.
During the first year, 31 patients accounted for 61 ER visits and 36 hospitalizations. Half of ER encounters were SLE-related and 20% infection-related, most were within 3 months of diagnosis (IQR 1-6). On univariable analysis, renal disease, pleurisy, gastrointestinal involvement, higher SLEDAI, high-dose steroids and antihypertensive use were associated with increased ER visits. Kidney and gastrointestinal involvement remained significant on multivariable analysis (Table 1). Although COI was not significant overall, all four high utilizers ( >3 ER visits) lived in low-opportunity neighborhoods (Table 2). Diagnosis location, renal involvement, and SLEDAI were associated with hospitalization on univariable analysis, with renal involvement remaining significant after adjustment. No deaths were reported.

Conclusion: In this single-center cSLE cohort, renal and gastrointestinal involvement were independently associated with higher acute care utilization during the first year after diagnosis. Findings in this study highlight the impact of early disease severity on healthcare burden and the importance of identifying high-risk utilizers early to enable proactive interventions. Limitations include small sample size and single-center design. Future multicenter are needed examine how neighborhood and non-medical drivers of health further influence healthcare utilization in cSLE.

Figure 1Supporting image 1Number of ER Visits within the first year of diagnosis by COI

Table 1Supporting image 2Factors associated with ER visit number within 1 year, multivariate negative binomial regression

Table 2Supporting image 3Patient Characteristics by ER Utilization Group


Disclosures: I. Miller: None; K. Nobleza: None; D. Nguyen: None; B. Van Horne: None; C. Greeley: None; M. DeGuzman: None; A. Thakral: None; O. Kwan: None; S. Molina: None.

To cite this abstract in AMA style:

Miller I, Nobleza K, Nguyen D, Van Horne B, Greeley C, DeGuzman M, Thakral A, Kwan O, Molina S. Acute Care Utilization in New-Onset Childhood Systemic Lupus Erythematosus: Insights from a Pilot Study [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 3). https://acrabstracts.org/abstract/acute-care-utilization-in-new-onset-childhood-systemic-lupus-erythematosus-insights-from-a-pilot-study/. Accessed .
  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to 2026 Pediatric Rheumatology Symposium

ACR Meeting Abstracts - https://acrabstracts.org/abstract/acute-care-utilization-in-new-onset-childhood-systemic-lupus-erythematosus-insights-from-a-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology